Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis — Stella

Home/Lupus Nephritis/CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

View on ClinicalTrials.gov

Recruiting

Back to Lupus Nephritis trials

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang

Key details

Phase

Very early testing

Sponsor

He Huang

Collaborators

Yake Biotechnology Ltd.

Enrollment target

~9 participants

Started

January 2025

Primary completion

October 2027

Age range

18 Years and older

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.